/LEGN
LEGN Stock - Legend Biotech Corporation
Healthcare|BiotechnologyNASDAQ
$21.92+3.01%
+$0.64 (+3.01%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+179.2%upside
Target: $61.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LEGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.70 – $22.14
TARGET (TP)$61.20
STOP LOSS$20.17
RISK/REWARD1:22.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.09
52W High$45.30
52W Low$21.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $627.24M | $285.14M | $117.00M | $68.83M | $75.00M |
| Gross Profit | $392.66M | $140.93M | $51.64M | $68.83M | $75.00M |
| Gross Margin | 62.6% | 49.4% | 44.1% | 100.0% | 100.0% |
| Operating Income | $-303,243,000 | $-439,485,000 | $-455,620,000 | $-392,287,000 | N/A |
| Net Income | $-177,026,000 | $-518,254,000 | $-446,349,000 | $-403,582,000 | $-266,373,000 |
| Net Margin | -28.2% | -181.8% | -381.5% | -586.4% | -355.2% |
| EPS | $-1.94 | $-5.88 | $-5.62 | $-5.48 | $-5.14 |
Company Overview
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
14
93%
Hold / Neutral
1
7%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
14 Bullish1 Neutral/Bearish
Price Targets
$73
Average Target
↑ 231.1% Upside
Now
$40
Low
$73
Average
$90
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 7th 2025 | Cantor Fitzgerald | Initiation | Overweight | $40 |
| October 8th 2024 | Redburn Atlantic | Initiation | Buy | $86 |
| June 17th 2024 | Truist | Initiation | Buy | $88 |
| May 24th 2024 | H.C. Wainwright | Reiterated | Buy | $73← $86 |
| May 23rd 2024 | Deutsche Bank | Initiation | Buy | $60 |
| April 17th 2024 | Scotiabank | Upgrade | Sector Outperform | $65 |
| April 3rd 2024 | Cantor Fitzgerald | Initiation | Overweight | $82 |
| March 13th 2024 | Raymond James | Initiation | Outperform | $86 |
| December 19th 2023 | Scotiabank | Initiation | Sector Perform | - |
| November 6th 2023 | Goldman | Initiation | Buy | $90.09 |
| May 25th 2023 | William Blair | Initiation | Market Perform | $64 |
| May 22nd 2023 | Daiwa Securities | Initiation | Buy | - |
| March 29th 2023 | H.C. Wainwright | Initiation | Buy | $66 |
| March 24th 2023 | RBC Capital Mkts | Initiation | Outperform | $73 |
| December 6th 2022 | UBS | Initiation | Buy | $66 |
Earnings History & Surprises
LEGNBeat Rate
69%
Last 16 quarters
Avg Surprise
+22.7%
EPS vs Estimate
Beats / Misses
11/5
Last 12 quarters
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q4 23
+69.6%
$-0.17vs$-0.56
Q1 24
+42.9%
$-0.40vs$-0.70
Q2 24
+44.8%
$-0.16vs$-0.29
Q3 24
+90.7%
$-0.05vs$-0.54
Q1 25
+61.5%
$-0.15vs$-0.39
Q2 25
+82.5%
$-0.07vs$-0.40
Q3 25
-54.5%
$-0.34vs$-0.22
Q4 25
+15.4%
$-0.11vs$-0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.13 | $-0.11 | +15.4% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.22 | $-0.34 | -54.5% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.40 | $-0.07 | +82.5% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-0.39 | $-0.15 | +61.5% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.54 | $-0.05 | +90.7% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.29 | $-0.16 | +44.8% | ✓ BEAT |
Q1 2024 | Mar 11, 2024 | $-0.70 | $-0.40 | +42.9% | ✓ BEAT |
Q4 2023 | Nov 20, 2023 | $-0.56 | $-0.17 | +69.6% | ✓ BEAT |
Q3 2023 | Aug 15, 2023 | $-0.69 | $-0.27 | +60.9% | ✓ BEAT |
Q2 2023 | May 18, 2023 | $-0.56 | $-0.40 | +28.6% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.44 | $-0.85 | -94.2% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | — | $-0.54 | — | — |
Q2 2022 | Jun 1, 2022 | $-0.37 | $-0.24 | +35.1% | ✓ BEAT |
Q1 2022 | Mar 18, 2022 | $-0.35 | $-0.38 | -8.6% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-0.60 | — | — |
Q4 2021 | Nov 16, 2021 | $-0.35 | $-0.43 | -22.9% | ✗ MISS |
Q3 2021 | Aug 23, 2021 | $-0.31 | $-0.32 | -3.2% | ✗ MISS |
Q2 2021 | May 18, 2021 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Latest News
Cantor Fitzgerald Maintains Overweight on Legend Biotech, Lowers Price Target to $74
➖ NeutralBenzinga•Dec 17, 2025, 02:55 PM
Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $50
➖ NeutralBenzinga•Dec 12, 2025, 05:15 PM
UBS Maintains Buy on Legend Biotech, Lowers Price Target to $48
➖ NeutralBenzinga•Dec 8, 2025, 03:18 PM•Also:
Reported Saturday, Legend Biotech Reports CARVYKTI 50.4-Month Median PFS In Triple-Class Exposed Multiple Myeloma And First-In-Human LUCAR-G39D Results In NHL
📈 PositiveBenzinga•Dec 8, 2025, 08:45 AM
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $90
➖ NeutralBenzinga•Nov 13, 2025, 08:28 PM•Also:
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $74
➖ NeutralBenzinga•Nov 13, 2025, 05:36 PM
Legend Biotech Announces Official Opening Of Its New R&D Facility In Philadelphia
📈 PositiveBenzinga•Nov 13, 2025, 05:14 PM
Cantor Fitzgerald Maintains Overweight on Legend Biotech, Raises Price Target to $75
📈 PositiveBenzinga•Nov 13, 2025, 02:08 PM
Legend Biotech Q3 Adj. EPS $(0.05) Beats $(0.10) Estimate, Sales $272.330M Miss $272.499M Estimate
➖ NeutralBenzinga•Nov 12, 2025, 12:00 PM
HC Wainwright & Co. Maintains Buy on Legend Biotech, Lowers Price Target to $60
📈 PositiveBenzinga•Oct 17, 2025, 10:43 AM
JP Morgan Maintains Overweight on Legend Biotech, Lowers Price Target to $76
📈 PositiveBenzinga•Oct 9, 2025, 01:45 PM•Also:
Legend Biotech Says Legend Biotech USA Enters Component And Product Supply Agreement With Janssen Pharmaceuticals; Legend Biotech USA To Make, Supply To Janssen Ciltacabtagene Autoleucel For Use Worldwide, Excluding Greater China; Cost For Commercial And Clinical Supply Of Cilta-cel Will Be Shared Equally By Legend Biotech USA And Janssen; JANSSEN WILL TRANSFER PRICE FOR CILTA-CEL BASED ON TOTAL COSTS TO PRODUCE, SUPPLY IT, PLUS SPECIFIED MARKUP
📈 PositiveBenzinga•Oct 7, 2025, 08:15 PM
'Legend Biotech Is Said to Explore Second Listing Outside of US'- Bloomberg
📈 PositiveBenzinga•Sep 5, 2025, 02:48 PM
Cantor Fitzgerald Assumes Legend Biotech at Overweight, Announces Price Target of $66
📈 PositiveBenzinga•Aug 27, 2025, 01:03 PM
JP Morgan Maintains Overweight on Legend Biotech, Raises Price Target to $78
📈 PositiveBenzinga•Aug 25, 2025, 02:07 PM•Also:
Legend Biotech Appoints Carlos Santos As CFO
➖ NeutralBenzinga•Aug 18, 2025, 12:01 PM
Frequently Asked Questions about LEGN
What is LEGN's current stock price?
Legend Biotech Corporation (LEGN) is currently trading at $21.92 per share. The stock has moved +3.01% today.
What is the analyst price target for LEGN?
The average analyst price target for LEGN is $61.20, based on 1 analyst.
What sector is Legend Biotech Corporation in?
Legend Biotech Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LEGN's market cap?
Legend Biotech Corporation has a market capitalization of $2.02 billion, making it a mid-cap company.
Does LEGN pay dividends?
No, Legend Biotech Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
ADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to LEGN for comparison